Bill Worzel, CEO & Chief Technology Officer
Bill Worzel, Chief Technology Officer, co-founded Genetics Squared in 2001 after 20 years of experience as both an inventor and an entrepreneur.

Worzel is a recognized leader in the field of genetic programming. Prior to launching Genetics Squared, Worzel was a leader of cutting edge research pursuing the commercialization of evolutionary algorithms. He authored Genetics Squared's original genetic programming patent and has led efforts to apply it in four separate areas of analysis.

He earned an MSc in computer science from The University of Cambridge in Cambridge, England.

Peter Lenehan, M.D., Ph.D., Chief Medical Officer
As Chief Medical Officer, Dr. Lenehan is responsible for establishing Genetics Squared's clinical strategy for diagnostics, prognostics, and therapeutics development.. Most recently, Dr. Lenehan was director of clinical oncology at Pfizer, where he led the early clinical development of many cancer therapies for solid tumors.

Dr. Lenehan brings a combined 24 years of basic cancer research and clinical oncology experience. Having conducted laboratory-based research in human leukemia at the Sloan-Kettering Institute for Cancer Research in NYC, he received a Ph.D. in 1982 and an M.D. in 1984 from SUNY Downstate Medical Center, Brooklyn, NY.

After completing his medical training at Jefferson Medical College in Philadelphia and a hematology-oncology fellowship at the University of Maryland Cancer Center in Baltimore, he joined the faculty of the University of Maryland School of Medicine. There, in the Laboratory of Developmental Therapeutics at the Cancer Center, he pursued basic research on the mechanisms of multi-drug resistance in human leukemia and clinical studies of novel anticancer compounds.

David W. Fry, Ph.D., Chief Science Officer
As Chief Science Officer, Dr. Fry leads the discovery of appropriate biomarkers and combinations of biomarkers to identify optimal patient populations for diagnostics, prognostics, and therapeutics. Most recently, Dr. Fry has been a lecturer and consultant on drug discovery and targeted therapy.

Prior to his consulting activities, Dr. Fry worked for 21 years in the pharmaceutical industry where he led oncology drug discovery efforts at Pfizer's Ann Arbor laboratories as a senior research fellow. During his tenure at Pfizer, his professional activities focused on target oriented drug discovery, biochemical mechanisms of anticancer agents, the role of signal transduction pathways in growth regulation, and oncogenesis and cell cycle regulation and its therapeutic application.

He has published more than 120 scientific manuscripts on drug discovery, biochemistry and pharmacology of anticancer agents and has co-authored 13 issued or pending patents. While at Parke-Davis, Dr. Fry was responsible for the discovery of several targeted cancer therapies that have advanced into clinical development.

James S. Arthurs, Operations Director

As Operations Director, Mr. Arthurs is responsible for management of all corporate processes. Prior to joining Genetics Squared, he was President of Biomedical Diagnostics, a start-up diagnostics product company. Mr. Arthurs has over 25 years of entrepreneurial and senior management experience in high-tech industries, and has been interim executive, business consultant, and advisor for a wide range of start-up and technology transfer endeavors.